Investment
Features
FeesSafety
Academy
More
Pluang+

Fortitude names Jaime Leverton CEO ahead of Nasdaq listing via HeartSciences merger

Market News
17 Sep 2026
Coindesk
View Source
Bullish
Fortitude names Jaime Leverton CEO ahead of Nasdaq listing via HeartSciences merger

Fortitude Mining Holdings appointed Jaime Leverton, former Hut 8 CEO, as its new CEO as it prepares for a Nasdaq listing through a merger with HeartSciences. Leverton will take over on September 21, with Andrea Childs moving to COO. The combined company is expected to be valued at around $400 million and will trade under the ticker 'TUDE'. Fortitude, focused on mining Zcash, produced about 28% of all ZEC mined in the first half of 2026 and reported $20.9 million in Q2 revenue. The merger is expected to close in Q4, pending shareholder approval.

The story about Fortitude Mining Holdings' new CEO Jaime Leverton is presented with market context from Pluang's platform. As of September 17, 2026, 44 out of 50 major cryptocurrencies on Pluang rose while 5 fell. Notable price changes include LUNC at Rp0,885 with a 4.71% increase and a typical hold time of 193 days, LTC at Rp939.378 with a 4.51% increase and a hold time of 77 days, and EGLD at Rp70.119 with a 4.40% increase and a hold time of 84 days.

More News

Lexeo Therapeutics to host event on clinical measures in PKP2 arrhythmogenic cardiomyopathy

Lexeo Therapeutics to host event on clinical measures in PKP2 arrhythmogenic cardiomyopathy

Lexeo Therapeutics announced an educational event on October 21, 2026, focusing on clinical endpoints and outcome measures in PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM). The event will feature discussions by Lexeo's Chief Medical Officer and a lea...

Others
Neutral
20 minutes ago
EyePoint's DURAVYU misses primary endpoint in wet AMD trial but shows reduced treatment burden and safety.

EyePoint's DURAVYU misses primary endpoint in wet AMD trial but shows reduced treatment burden and safety.

EyePoint announced that its DURAVYU treatment for wet age-related macular degeneration (wet AMD) did not meet the primary goal of matching the visual improvement of the standard aflibercept treatment in the LUCIA Phase 3 trial. However, DURAVYU demon...

Company Fundamentals
Neutral
20 minutes ago
Marker Therapeutics wins $2.6M FDA grant to advance MT-601 therapy for pancreatic cancer.

Marker Therapeutics wins $2.6M FDA grant to advance MT-601 therapy for pancreatic cancer.

Marker Therapeutics has been awarded a $2.6 million grant from the FDA's Orphan Products Clinical Trials program to support a Phase 1 study of its MT-601 multi-antigen recognizing T cell therapy for locally advanced unresectable pancreatic cancer. Th...

Market News
Bullish
20 minutes ago
Agility Robotics appoints Mark Vale as audit committee chair ahead of public listing.

Agility Robotics appoints Mark Vale as audit committee chair ahead of public listing.

Agility Robotics announced that Mark Vale, former UPS president and current CEO of Transportation Insight, will join its board and chair the audit committee after its merger with Churchill Capital Corp XI. Vale's extensive experience in global logist...

Company Fundamentals
Bullish
20 minutes ago
JazzCash wins Silver Award for innovation in InsurTech at Money20/20 USA 2026

JazzCash wins Silver Award for innovation in InsurTech at Money20/20 USA 2026

JazzCash, Pakistan's leading digital financial services platform, won the Silver Award in the Banking – InsurTech category at Money20/20 USA 2026 for its health-protection platform Sehat+. This platform provides affordable health insurance to Pakista...

Market News
Bullish
20 minutes ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App